close
ONCOLOGY
Expert Insight View All

Stride with dual immunotherapy and more: the new and evolving SoC for uHCC management

Multi-kinase inhibitors including sorafenib and lenvatinib were the first-line systemic treatment options for unresectable hepatocellular carcinoma (uHCC) patients, albeit with a median overall survival (OS) of around 1 year.1 Following the regulatory approval based on the significant OS improvement in 2020, atezolizumab + bevacizumab (atezo/bev) became a new and current standard of care (SoC) for uHCC.1 Despite the tremendous advancement, additional systemic treatment options with long-term efficacy and well tolerated safety profiles are still warranted to cater for individual medical needs of uHCC patients.2 Very recently, a novel immunotherapy (IO) combination (i.e., the STRIDE regimen) featuring a single high-priming dose of tremelimumab (TREME) [an anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)] and every-4-week durvalumab (DUR) (anti-PD-L1) showed encouraging clinical efficacy and high tolerability in a phase 3 trial, becoming the latest addition to the armamentarium of first-line systemic treatment options for uHCC patients.2 In the 4th AGM and HBP workshop organized by the Hong Kong Stereotactic Body Radiation Therapy (SBRT) Study Group, Professor Arndt Vogel and Dr. Chiang, Chi-Leung presented new data and discussed the latest advancement in the rapidly evolving treatment landscape of uHCC. Subsequently in an interview with Omnihealth Practice, Dr. Chiang shared his insights into the new dual IO treatment option in uHCC. He also provided updates on the ongoing study START-FIT [transarterial chemoembolization (TACE) + SBRT + dual IO] with promising early results. At the end of the interview, he shared a clinical case which demonstrated the remarkable efficacy of SBRT + dual IO in a local uHCC patient

11 Jan 2023
thumb

Dr. Chiang, Chi-Leung

Clinical Assistant Professor,
Department of Clinical Oncology,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

thumb

Professor Arndt Vogel

Senior Consultant and Professor,
Department of Gastroenterology, Hepatology and Endocrinology,
Hannover Medical School
Head of the GI-Cancer Center,
Hannover Medical School,
Germany

Conference Update View All
Meeting Highlight View All

Adopting durvalumab consolidation therapy: A breakthough for non-small cell lung cancer treatment

thumb

Dr. Lee, Ho-Fun Victor

Clinical Associate Professor,
Department of Clinical Oncology,
The University of Hong Kong

thumb

Dr. Chan, Siu-Hong Oscar

Specialist in Clinical Oncology,
Hong Kong Integrated Oncology Centre

thumb

Dr. Nyaw, Shi-Feng Jonathan

Specialist in Clinical Oncology,
Department of Clinical Oncology,
Tuen Mun Hospital

Infographics View All

Fiber-rich diet associated with better response to immunotherapy in patients with melanoma

25 Feb 2022